Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carrimycin in advanced head and neck squamous cell carcinoma
NCT04413214Phase 1Completed
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Dec 2019
- Primary completion
- Dec 2022
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of carrimycin in head and neck squamous cell carcinoma (HNSCC), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoints: Incidence of treatment-emergent adverse events at 2 years and Dose limiting toxicity at 4 weeks. Started Dec 2019; status: completed.
02
Drugs
carrimycin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04413214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04413214.